Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of September 2025

	30.09.2025	31.12.2024
ASSETS	*BGN'000*	*BGN'000*
Non-current assets		
Property, plant and equipment	32 362	33 304
Intangible assets	3 638	2 836
Investments in subsidiaries	69	69
Trade receivables	5 403	5 403
Total non-current assets	**42 472**	**41 612**
Current assets		
Inventories	16 742	15 862
Trade and other receivables	74 386	70 822
Current corporate income tax	-	129
Cash and cash equivalents	310	79
Total current assets	**91 438**	**86 892**
Total assets	**133 910**	**128 504**
LIABILITIES		
Equity		
Share capital	95 900	91 800
Reserves	13 549	13 147
Retained earnings	6 598	4 552
Total	**116 047**	**109 449**
Non-current liabilities		
Long-term loans	1 146	675
Deferred tax liabilities	1 198	1 198
Retirement benefit obligations	268	268
Total non-current liabilities	**2 612**	**2 141**
Current liabilities		
Trade and other liabilities	3 896	6 337
Short-term loans	9 778	9 784
Current portion of long-term loans	922	670
Other tax liabilities	655	123
Total current liabilities	**15 251**	**16 914**
Total liabilities	**17 863**	**19 055**
Total equity and liabilities	**133 910**	**128 504**

Date of preparation: 28.10.2025
Sofia

Prepared by:............... Executive Director:..................
/Ts. Pandeva/ /B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of September 2025

	30.09.2025	30.09.2024
	BGN'000	*BGN'000*
Revenue	47 984	40 414
Other income	2	182
Total income	**47 986**	**40 596**
Carrying amount of goods sold	(2 260)	(1 953)
Changes in inventories of finished products and work in progress	14	318
Materials and services	(27 826)	(24 712)
Personnel expenses	(7 868)	(6 664)
Depreciation / amortisation expenses	(2 129)	(1 877)
Other expenses	(470)	(434)
Finance income	78	40
Finance costs	(432)	(550)
Total expenses	**(40 893)**	**(35 832)**
Profit before taxation	**7 093**	**4 764**
Corporate income tax expense	(495)	(420)
Profit/Loss for the period	**6 598**	**4 344**
Total comprehensive income for the period	**6 598**	**4 344**
Earnings per share / in BGN per 1 share /	0.07	0.05

Date of preparation: 28.10.2025
Sofia

Prepared by:...............
/Ts. Pandeva/

Executive Director:.................
/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of September 2025

	30.09.2025	**30.09.2024**
	BGN'000	***BGN'000***
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	35 433	30 227
Payments to suppliers of materials, goods and services	(19 061)	(15 642)
Payments to personnel	(8 020)	(6 832)
Foreign currency exchange gains/losses	(21)	(26)
Payments of interest and dividends	(366)	(408)
Other proceeds / payments	(6 042)	(4 704)
Net cash flows	**1 923**	**2 615**
Cash flows from investing activities		
Payments on non-current assets acquired	(975)	(1 687)
Other post/payments for investment activity		(50)
Net cash flows	**(975)**	**(1 737)**
Cash flows from financial activities		
Proceeds from loans	341	438
Payments on loans	(343)	(446)
Payment of interest, dividends	(323)	(428)
Payments on finance lease	(392)	(391)
Net cash flows	**(717)**	**(827)**
Change in cash and cash equivalents	**231**	**51**
Cash and cash equivalents at the beginning of the period	**79**	**60**
Cash and cash equivalents at the end of the period	**310**	**111**

Date of preparation: 28.10.2025
Sofia

Prepared by:......... ....
/Ts. Pandeva/

Executive Director:...................
/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of September 2025

	Registered (share) capital *BGN'000*	Revaluation reserves *BGN'000*	Other reserves *BGN'000*	Retained earnings / loss *BGN'000*	Total equity *BGN'000*
Balance as of 01.01.2024	**84 500**	**4 369**	**8 431**	**7 707**	**105 007**
Profit/loss for the period				4 492	**4 492**
Other comprehensive income		(50)			**(50)**
Including from tax effect of the revaluation of property, plant and equipment					
Total comprehensive income		**(50)**		**4 492**	**4 442**
Issue of shares by the owners	7 300		347	(7 647)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period	**7 300**		**347**	**(7 647)**	
Balance as of 31.12.2024	**91 800**	**4 319**	**8 778**	**4 552**	**109 449**
Balance as of 01.01.2025	**91 800**	**4 319**	**8 778**	**4 552**	**109 449**
Profit/loss for the period				6 598	6 598
Other comprehensive income					
Total comprehensive income				**6 598**	**6 598**
Issue of shares by the owners	4 100		452	(4 552)	
Total amount of income and expenses recognised during the period					
Balance as of 30.09.2025	**95 900**	**4 319**	**9 230**	**6 598**	**116 047**

Date of preparation: 28.10.2025
Sofia

Prepared by:............................
/Ts. Pandeva/

Executive Director:............................
/B. Georgiev /